Rheumnow
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:05:04
- Mas informaciones
Informações:
Sinopsis
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
